Switch theme
Sign up to access all valuation multiples
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology. It operates as a single segment, which is Development of Radiopharmaceuticals. Geographically, it operates in Australia and the United States.
2010
n/a
LTM Revenue $3.1M
LTM EBITDA -$35.4M
$374M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Clarity Pharmaceuticals has a last 12-month revenue (LTM) of $3.1M and a last 12-month EBITDA of -$35.4M.
In the most recent fiscal year, Clarity Pharmaceuticals achieved revenue of n/a and an EBITDA of -$36.1M.
Clarity Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Clarity Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $3.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$35.4M | XXX | -$36.1M | XXX | XXX | XXX |
| EBITDA Margin | -1138% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$35.4M | XXX | -$36.2M | XXX | XXX | XXX |
| EBIT Margin | -1138% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$33.6M | XXX | -$27.2M | XXX | XXX | XXX |
| Net Margin | -1081% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Clarity Pharmaceuticals's stock price is AUD 2 (or $1).
Clarity Pharmaceuticals has current market cap of AUD 694M (or $446M), and EV of AUD 583M (or $374M).
See Clarity Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $374M | $446M | XXX | XXX | XXX | XXX | $-0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Clarity Pharmaceuticals has market cap of $446M and EV of $374M.
Clarity Pharmaceuticals's trades at n/a EV/Revenue multiple, and -10.4x EV/EBITDA.
Equity research analysts estimate Clarity Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Clarity Pharmaceuticals has a P/E ratio of -13.3x.
See valuation multiples for Clarity Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $446M | XXX | $446M | XXX | XXX | XXX |
| EV (current) | $374M | XXX | $374M | XXX | XXX | XXX |
| EV/Revenue | 120.3x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -10.6x | XXX | -10.4x | XXX | XXX | XXX |
| EV/EBIT | -10.6x | XXX | -10.3x | XXX | XXX | XXX |
| EV/Gross Profit | 120.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -13.3x | XXX | -14.5x | XXX | XXX | XXX |
| EV/FCF | -11.6x | XXX | -12.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialClarity Pharmaceuticals's last 12 month revenue growth is 2%
Clarity Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Clarity Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Clarity Pharmaceuticals's rule of X is -1133% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Clarity Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -1138% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 37% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1133% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Clarity Pharmaceuticals acquired XXX companies to date.
Last acquisition by Clarity Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Clarity Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Clarity Pharmaceuticals founded? | Clarity Pharmaceuticals was founded in 2010. |
| Where is Clarity Pharmaceuticals headquartered? | Clarity Pharmaceuticals is headquartered in Australia. |
| Who is the CEO of Clarity Pharmaceuticals? | Clarity Pharmaceuticals's CEO is Ms. Michelle Parker. |
| Is Clarity Pharmaceuticals publicy listed? | Yes, Clarity Pharmaceuticals is a public company listed on ASX. |
| What is the stock symbol of Clarity Pharmaceuticals? | Clarity Pharmaceuticals trades under CU6 ticker. |
| When did Clarity Pharmaceuticals go public? | Clarity Pharmaceuticals went public in 2021. |
| Who are competitors of Clarity Pharmaceuticals? | Similar companies to Clarity Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Clarity Pharmaceuticals? | Clarity Pharmaceuticals's current market cap is $446M |
| What is the current revenue of Clarity Pharmaceuticals? | Clarity Pharmaceuticals's last 12 months revenue is $3.1M. |
| What is the current revenue growth of Clarity Pharmaceuticals? | Clarity Pharmaceuticals revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Clarity Pharmaceuticals? | Current revenue multiple of Clarity Pharmaceuticals is 120.3x. |
| Is Clarity Pharmaceuticals profitable? | Yes, Clarity Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Clarity Pharmaceuticals? | Clarity Pharmaceuticals's last 12 months EBITDA is -$35.4M. |
| What is Clarity Pharmaceuticals's EBITDA margin? | Clarity Pharmaceuticals's last 12 months EBITDA margin is -1138%. |
| What is the current EV/EBITDA multiple of Clarity Pharmaceuticals? | Current EBITDA multiple of Clarity Pharmaceuticals is -10.6x. |
| What is the current FCF of Clarity Pharmaceuticals? | Clarity Pharmaceuticals's last 12 months FCF is -$32.4M. |
| What is Clarity Pharmaceuticals's FCF margin? | Clarity Pharmaceuticals's last 12 months FCF margin is -1041%. |
| What is the current EV/FCF multiple of Clarity Pharmaceuticals? | Current FCF multiple of Clarity Pharmaceuticals is -11.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
